Hereditary Hemochromatosis Management

Diagnostic Criteria

• The American Association for the Study of Liver Diseases recommends diagnostic criteria for hereditary hemochromatosis, including elevated transferrin saturation (>45% in females, >50% in males), elevated ferritin (>200 μg/L in females, >300 μg/L in males), and genetic testing showing C282Y homozygosity or C282Y/H63D compound heterozygosity 1, 2
• Comprehensive iron studies should include serum iron, transferrin, transferrin saturation, serum ferritin, C-reactive protein, hepcidin levels, and red blood cell morphology, according to the Clinical Nutrition guidelines 3
• Genetic testing for HFE mutations (C282Y, H63D) may be considered to confirm hereditary hemochromatosis, especially in patients with a family history of the condition, as recommended by the American College of Medical Genetics 4

Pre-treatment Assessment and Monitoring

• The European Association for the Study of the Liver suggests evaluating liver fibrosis status and screening for end-organ damage (liver, heart, pancreas, joints) in patients with hereditary hemochromatosis, with assessment for hepatocellular carcinoma in patients with cirrhosis 1, 5
• The American College of Gastroenterology recommends monitoring hemoglobin at each phlebotomy session to avoid anemia, and checking ferritin every 3-4 months to maintain ferritin <100 μg/L 1
• Regular cardiac evaluation for patients with significant iron overload is necessary to detect early cardiomyopathy, as suggested by the American College of Cardiology 6
• Patients with cirrhosis due to iron overload should undergo regular screening for hepatocellular carcinoma, as recommended by the American Association for the Study of Liver Diseases 2

Treatment and Prognosis

• The American Gastroenterological Association recommends therapeutic phlebotomy as the primary treatment for hereditary hemochromatosis, with an initial induction phase targeting ferritin levels <50 μg/L, and maintenance therapy to keep ferritin <100 μg/L 1
• Early diagnosis and treatment are crucial for preventing complications, with survival rates comparable to the general population when treatment is initiated before the development of cirrhosis or diabetes 2
• The target for maintenance therapy is to maintain serum ferritin ≤50 μg/L, with monitoring of ferritin levels every 3-4 months 2
• Iron chelation therapy with deferasirox should be initiated for patients who have received multiple blood transfusions (>20 units) with serum ferritin levels >1000 ng/mL to prevent organ damage and mortality, as recommended by the National Comprehensive Cancer Network 7
• Deferoxamine can be used at 20-40 mg/kg body weight per day for iron chelation therapy, as recommended by the American College of Cardiology and the American Journal of Hematology for adults with aplastic anemia when serum ferritin levels reach 1,000 ng/mL 6, 8

Special Considerations

• The American Association for the Study of Liver Diseases suggests that first-degree relatives of patients with hereditary hemochromatosis should be offered genetic testing after 18 years of age, particularly for siblings who have a 33% chance of being homozygous for the C282Y mutation 9
• Liver transplantation may be necessary for patients with decompensated cirrhosis, though post-transplant survival rates are lower in hemochromatosis patients compared to those transplanted for other conditions 5
• Dietary modifications, including avoiding iron supplements and iron-fortified foods, limiting red meat consumption, and restricting alcohol intake, can help manage iron overload, as recommended by the American Association for the Study of Liver Diseases and the European Association for the Liver 2, 4, 1
• Vitamin C supplements should be avoided during treatment as they enhance iron absorption 2
• During pregnancy, the target ferritin level should remain ≥50 μg/L, as recommended by the European Association for the Study of the Liver 10
• Definitive iron deficiency is defined as a ferritin level <15 μg/L (specificity 98%), and probable iron deficiency in inflammatory states is defined as a ferritin level <100 μg/L, and risk of iron overload is defined as a ferritin level >300 μg/L in the absence of inflammation, as suggested by the American College of Cardiology and the European Association for the Study of the Liver 11, 12

Monitoring and Maintenance

• The goal of iron chelation therapy is to decrease serum ferritin to <1000 ng/mL, prevent iron-mediated organ dysfunction (cardiac, hepatic, endocrine), and maintain negative iron balance, as recommended by the National Comprehensive Cancer Network and the American Journal of Hematology 7, 8
• Regular monitoring should include serum ferritin every 3 months, renal function monthly (weekly for the first month in high-risk patients), and liver function tests every 2 weeks during the first month, then monthly 7
• Monitoring transfusion burden is critical through blood bank transfusion tracking data, personal RBC transfusion diary, and automatic alerts after 20 units of blood, according to the American Journal of Hematology 8

Target Parameters

1, 4